🔎 Trials Near Me

Почетна › Немалоклетни карцином плућа › Arizona

Kliničke studije za Немалоклетни карцином плућа u državi Arizona

67 studija za Немалоклетни карцином плућа traži učesnike na lokacijama u državi Arizona.

Gradovi u državi Arizona

Zvanični tekst studije (na engleskom)

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

  • HonorHealth Research Institute, Scottsdale
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT07659782

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  • Research Site, Chandler
  • Research Site, Gilbert
  • Research Site, Goodyear
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07291037

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

  • Western Regional Medical Center, LLC, Goodyear
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06216301

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  • Banner MD Anderson Cancer Center ( Site 0181), Gilbert
  • The University of Arizona Cancer Center - North Campus ( Site 0163), Tucson
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT06623422

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  • Southern Arizona VA Health Care System, Tucson
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT06561386

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  • City of Hope - Phoenix, Goodyear
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06793215

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  • City of Hope, Phoenix, Phoenix
  • The University of Arizona Cancer Center - North Campus, Tucson
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06890598

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

  • Mayo Clinic Hospital - Arizona, Phoenix
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06706076

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • USOR HonorHealth, Phoenix
  • USOR Arizona Oncology Associates, Tucson
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • Kingman Regional Medical Center, Kingman
  • Cancer Center at Saint Joseph's, Phoenix
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06418204

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  • HonorHealth, Scottsdale
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06400472

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • Banner MD Anderson Cancer Center, Gilbert
  • Banner University Medical Center Phoenix, Phoenix
  • The University of Arizona Cancer Center - North Campus, Tucson
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06119581

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

  • Honor Health Research Institute, Scottsdale
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07397338

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

  • Banner Health, Tucson
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06060613

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

  • Mayo Clinic in Arizona - Phoenix ( Site 0147), Phoenix
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06170788

A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

  • HonorHealth Research Institute (#600), Scottsdale
Тражи се учесникФаза 1/2
Узраст од 18 до 75 · Оба пола · Ажурирано 3. 11. 2026. · NCT07636785

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

  • Mayo Clinic, Phoenix, Phoenix
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06720987

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  • Local Institution - 007-556-A, Goodyear
  • USOR - Arizona Oncology - Prescott Valley, Prescott Valley
  • Local Institution - 007-568-A, Safford
  • и још 5
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT04613596

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

  • University of Arizona Cancer Center, Tucson
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT05098132

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  • Research Site, Tucson
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06692738

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

  • Research Site, Phoenix
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06996782

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

  • Research Site, Tucson
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06357533

Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

  • HonorHealth Research Institute, Scottsdale
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT07751042

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

  • Banner Health, Gilbert
  • Mayo Clinic Hospital, Phoenix
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT04981119

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  • Mohtaseb Cancer Center & Blood Disorders, Bullhead City
  • Palo Verde Hematology Oncology, Glendale
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT07361510

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Cancer Treatment Centers of America, Phoenix, Goodyear
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT07154290

A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

  • HonorHealth Research Institute, Scottsdale
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT07705334

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  • Ironwood Cancer and Research Center /ID# 276370, Chandler
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT06568939

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

  • Mayo Clinic Scottsdale, Scottsdale
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 21. 10. 2026. · NCT06810544

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

  • Research Site 111, Tucson
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 21. 10. 2026. · NCT05914116

AOH1996 for the Treatment of Refractory Solid Tumors

  • Honor Health Research and Innovation Institute, Scottsdale
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 20. 10. 2026. · NCT05227326

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  • Banner MD Anderson Cancer Center, Gilbert
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 19. 10. 2026. · NCT06162221

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

  • CTCA at Western Regional Medical Center, Goodyear
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT07288034

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

  • Mayo Clinic Comprehensive Cancer Center, Phoenix
  • University of Arizona, Tucson
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT06026410

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  • Banner Health- MD Anderson Cancer Center, Gilbert
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT05786924

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  • Mayo Clinic Arizona, Phoenix
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT07070232

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • Banner University Medical Center - Tucson, Tucson
  • University of Arizona Cancer Center-North Campus, Tucson
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT06616584

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Pioneer Research Center, Bullhead City
  • Ironwood Cancer & Research Centers, Chandler
  • Ironwood Cancer & Research Centers, Gilbert
  • и још 6
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07222566

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

  • Banner MD Anderson Cancer Center, Gilbert
  • Arizona Cancer Center at UMC North/University Medical Center, Tucson
Тражи се учесникФаза 1/2
Узраст од 18 до 99 · Оба пола · Ажурирано 6. 10. 2026. · NCT06814496

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

  • Banner MD Anderson Cancer Center, Gilbert
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT06784193

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.